Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy

Published:2024-09 Issue:9 Volume:24 Page:e314-e319
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Handa Shivani^ORCID,Sivakumar Ganesh,Srisuwananukorn Andrew^ORCID,Dueck Amylou,Tremblay Douglas,Mascarenhas John O^ORCID,Ginzburg Yelena,Kremyanskaya Marina^ORCID,Hoffman Ronald^ORCID

Publisher

Elsevier BV

Reference23 articles.

1. The clinical dilemma of JAK inhibitor failure in myelofibrosis: predictive characteristics and outcomes;Mascarenhas;Cancer,2022

2. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial;Verstovsek;J Hematol Oncol,2017

3. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis [published correction appears in Leukemia. 2017 Mar;31(3):775];Harrison;Leukemia,2016

4. Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges;Ajufo;Ther Adv Hematol,2023

5. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells;Wang;Blood,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP